Who

[Who @hithopadesa]

@Ashwinreads @Barclays Her views on inhibiting INHBE and ALK-7 as potential therapies

[Who @hithopadesa]

@JoseRestonVA What's the other one, sir?

[Who @hithopadesa]

@hannibalspeaks Brilliant!

[Who @hithopadesa]

@plainyogurt21 Thank you! Very useful

[Who @hithopadesa]

@ValueForAll1 Interesting. Thanks. What do you think would be the BO price, and why?

[Who @hithopadesa]

@PrestonWidmer @deathtouch2k @johnkmason Thank you! How do the cancer rates for jaks compare to cancer rates in 50 mg arm of Obi?

[Who @hithopadesa]

@deathtouch2k @johnkmason Could you kindly explain how JAKs have a much worse safety profile? If cancer risk is real, and if prolonged use of 25mg dose beyond a year may also lead to cancer cases, would Obi be used extensively, given availability of alternatives and drugs in the pipeline?

[Who @hithopadesa]

@PersimmonTI You ain't seen nothing yet!

[Who @hithopadesa]

@ValueForAll1 Could you please explain what redom could lead do? Are you referring to an acquisition?

[Who @hithopadesa]

@meremrtl Thanks!

[Who @hithopadesa]

@meremrtl Thanks for sharing! What could be its value if it's acquired?

[Who @hithopadesa]

@rxgongivit2ya Thanks for your insights! Can you share your thoughts on Relay's Zovega?

[Who @hithopadesa]

@rxgongivit2ya Could you please share your thoughts on Relay therapeutics? Their Phase 2 data seem strong. Phase 3 in 2L setting is ongoing.

[Who @hithopadesa]

@BiotechTV Interesting. Thanks

[Who @hithopadesa]

@rxgongivit2ya Could you please share your opinion on Relay therapeutics?

[Who @hithopadesa]

@valuephilos Your thoughts on Adobe's stock at current levels?

[Who @hithopadesa]

@valuephilos Check out Solt DB if you are interested - https://t.co/IEiWQU7e7z

[Who @hithopadesa]

@valuephilos Congrats again! Looking forward to the updated article.

[Who @hithopadesa]

@Driller562 Thanks! Any thoughts on how to short oil without options/derivatives?

[Who @hithopadesa]

@Driller562 Are you shorting through SCO?